Renata C.F. Bonatti

Learn More
BACKGROUND Mucopolysaccharidosis type VI (MPS VI) is a progressive, chronic and multisystem lysosomal storage disease with a wide disease spectrum. Clinical and biochemical improvements have been reported for MPS VI patients on enzyme replacement therapy (ERT) with rhASB (recombinant human arylsulfatase B; galsulfase, Naglazyme®, BioMarin Pharmaceutical(More)
Enzyme replacement therapy with galsulfase in 34 children younger than five years of age with MPS VI Dafne D.G. Horovitz ⁎, Tatiana S.P.C. Magalhães , Angelina Acosta , Erlane M. Ribeiro , Liane R. Giuliani , Durval B. Palhares , Chong A. Kim , Ana Carolina de Paula , Marcelo Kerstenestzy , Mara A.D. Pianovski , Maria Ione F. Costa , Francisca C. Santos ,(More)
  • 1